{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:18:34Z","timestamp":1783606714101,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T00:00:00Z","timestamp":1706400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ejps.2024.106713","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T11:47:55Z","timestamp":1706788075000},"page":"106713","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Evaluation of omadacycline dosing regimens in Chinese using population pharmacokinetic-pharmacodynamic analysis"],"prefix":"10.1016","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2609-6058","authenticated-orcid":false,"given":"Kun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengling","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Reinhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejps.2024.106713_bib0033","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/jac\/dkz267","article-title":"Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus","volume":"74","author":"Bax","year":"2019","journal-title":"J. Antimicrob. Chemother"},{"issue":"2","key":"10.1016\/j.ejps.2024.106713_bib0018","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS. J."},{"key":"10.1016\/j.ejps.2024.106713_bib0027","series-title":"Pharmacokinetic-pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients With Community-Acquired Bacterial Pneumonia for Streptococcus penumoniae and Haemophilus influenzae","author":"Bhavnani","year":"2018"},{"key":"10.1016\/j.ejps.2024.106713_bib0026","unstructured":"Bhavnani, S., et al., Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacteridal skin and skin structure infections. [poster no. 1944]. 2019. 29th European Congress of Clinical Microbiology and Infectious Diseases; Amsterdam."},{"issue":"3","key":"10.1016\/j.ejps.2024.106713_bib0004","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1358\/dot.2018.54.3.2800620","article-title":"Return of the tetracyclines: omadacycline, a novel aminomethylcycline antimicrobial","volume":"54","author":"Cho","year":"2018","journal-title":"Drugs Today (Barc)"},{"issue":"8","key":"10.1016\/j.ejps.2024.106713_bib0023","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s10096-020-03877-w","article-title":"In vitro activity of omadacycline against pathogens isolated from Mainland China during 2017-2018","volume":"39","author":"Dong","year":"2020","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"3","key":"10.1016\/j.ejps.2024.106713_bib0003","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1128\/AAC.01066-13","article-title":"Mechanism of action of the novel aminomethylcycline antibiotic omadacycline","volume":"58","author":"Draper","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl 5","key":"10.1016\/j.ejps.2024.106713_bib0034","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1086\/431675","article-title":"The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam","volume":"41","author":"Ellis-Grosse","year":"2005","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.ejps.2024.106713_bib0019","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/j.1552-4604.1997.tb04326.x","article-title":"Stability and performance of a population pharmacokinetic model","volume":"37","author":"Ette","year":"1997","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106713_bib0014","unstructured":"FDA, NUZYRA (omadacycline), https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209816_209817lbl.pdf. 2018."},{"issue":"9","key":"10.1016\/j.ejps.2024.106713_bib0022","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01135-17","article-title":"Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects","volume":"61","author":"Gotfried","year":"2017","journal-title":"Antimicrob. Agents Chemother"},{"issue":"4","key":"10.1016\/j.ejps.2024.106713_bib0001","article-title":"The novel aminomethylcycline omadacycline has high specificity for the primary tetracycline-binding site on the bacterial ribosome","volume":"5","author":"Heidrich","year":"2016","journal-title":"Antibiotics. (Basel)"},{"issue":"11","key":"10.1016\/j.ejps.2024.106713_bib0002","doi-asserted-by":"crossref","first-page":"7044","DOI":"10.1128\/AAC.01536-15","article-title":"Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline","volume":"59","author":"Honeyman","year":"2015","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.ejps.2024.106713_bib0030","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jgar.2019.02.017","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: results from the SENTRY Antimicrobial Surveillance Programme, 2017","volume":"19","author":"Huband","year":"2019","journal-title":"J. Glob. Antimicrob. Resist."},{"issue":"7","key":"10.1016\/j.ejps.2024.106713_bib0006","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02263-19","article-title":"Population pharmacokinetic analyses for omadacycline using phase 1 and 3 data","volume":"64","author":"Lakota","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.ejps.2024.106713_bib0009","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1080\/07853890.2022.2085881","article-title":"Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance","volume":"54","author":"LaPlante","year":"2022","journal-title":"Ann. Med."},{"issue":"7","key":"10.1016\/j.ejps.2024.106713_bib0025","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00624-19","article-title":"In vivo pharmacodynamics of omadacycline against staphylococcus aureus in the neutropenic murine thigh infection model","volume":"63","author":"Lepak","year":"2019","journal-title":"Antimicrob. Agents Chemother"},{"issue":"1","key":"10.1016\/j.ejps.2024.106713_bib0021","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01784-16","article-title":"Pharmacokinetics, distribution, metabolism, and excretion of omadacycline following a single intravenous or oral dose of 14C-omadacycline in rats","volume":"61","author":"Lin","year":"2017","journal-title":"Antimicrob. Agents Chemother"},{"issue":"3","key":"10.1016\/j.ejps.2024.106713_bib0017","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-Toolkit\u2013a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM","volume":"79","author":"Lindbom","year":"2005","journal-title":"Comput. Methods Programs Biomed."},{"issue":"3","key":"10.1016\/j.ejps.2024.106713_bib0010","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/jps.23872","article-title":"Determination of atypical nonlinear plasma-protein-binding behavior of tigecycline using an in vitro microdialysis technique","volume":"103","author":"Mukker","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2024.106713_bib0013","unstructured":"NMPA, https:\/\/www.cde.org.cn\/main\/xxgk\/postmarketpage?acceptidCODE=18263d22c076c5071d215fe565152d87."},{"key":"10.1016\/j.ejps.2024.106713_bib0012","author":"Paratek","year":"2021","journal-title":"Nuzyra (omadacycline) Package Insert"},{"issue":"4","key":"10.1016\/j.ejps.2024.106713_bib0031","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02327-17","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the united states and europe as part of the 2016 SENTRY antimicrobial surveillance program","volume":"62","author":"Pfaller","year":"2018","journal-title":"Antimicrob. Agents Chemother"},{"issue":"5","key":"10.1016\/j.ejps.2024.106713_bib0029","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02488-19","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: report from the SENTRY antimicrobial surveillance program, 2016 to 2018","volume":"64","author":"Pfaller","year":"2020","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.ejps.2024.106713_bib0028","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jgar.2021.09.011","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY Antimicrobial Surveillance Program, 2019","volume":"27","author":"Pfaller","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"issue":"4","key":"10.1016\/j.ejps.2024.106713_bib0015","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40262-019-00843-4","article-title":"Omadacycline: a Review of the Clinical Pharmacokinetics and Pharmacodynamics","volume":"59","author":"Rodvold","year":"2020","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.ejps.2024.106713_bib0005","doi-asserted-by":"crossref","first-page":"ofab136","DOI":"10.1093\/ofid\/ofab136","article-title":"Clinical efficacy of patients with secondary bacteremia treated with omadacycline: results from phase 3 acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia studies","volume":"8","author":"Sakoulas","year":"2021","journal-title":"Open. Forum. Infect. Dis."},{"issue":"3","key":"10.1016\/j.ejps.2024.106713_bib0020","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","article-title":"Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions","volume":"11","author":"Savic","year":"2009","journal-title":"AAPS. J."},{"issue":"5","key":"10.1016\/j.ejps.2024.106713_bib0016","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/BF01061030","article-title":"Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data","volume":"9","author":"Sheiner","year":"1981","journal-title":"J. Pharmacokinet. Biopharm."},{"issue":"4","key":"10.1016\/j.ejps.2024.106713_bib0011","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijantimicag.2016.12.008","article-title":"A need to revisit clinical breakpoints of tigecycline: effect of atypical non-linear plasma protein binding","volume":"49","author":"Singh","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"6","key":"10.1016\/j.ejps.2024.106713_bib0032","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ejps.2024.106713_bib0008","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/jcph.814","article-title":"Effect of food on the bioavailability of omadacycline in healthy participants","volume":"57","author":"Tzanis","year":"2017","journal-title":"J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejps.2024.106713_bib0024","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02265-19","article-title":"Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection Model","volume":"64","author":"VanScoy","year":"2020","journal-title":"Antimicrob. Agents Chemother"},{"issue":"3","key":"10.1016\/j.ejps.2024.106713_bib0007","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40265-020-01257-4","article-title":"Omadacycline: a novel oral and intravenous aminomethylcycline antibiotic agent","volume":"80","author":"Zhanel","year":"2020","journal-title":"Drugs"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724000241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724000241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:09:19Z","timestamp":1760530159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098724000241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":34,"alternative-id":["S0928098724000241"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106713","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of omadacycline dosing regimens in Chinese using population pharmacokinetic-pharmacodynamic analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106713","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106713"}}